Anastrozole (Arimidex)

Anastrozole, sold as Arimidex, is a non-steroidal aromatase inhibitor: a prescription breast-cancer drug that lowers the body’s estrogen by blocking the enzyme that makes it. It helps to be clear about what anastrozole is and isn’t. It is not an anabolic-androgenic steroid (a muscle-building hormone), not a SERM (a selective estrogen receptor modulator, like tamoxifen), and not a peptide. It has solid evidence from large trials in postmenopausal women with breast cancer — and a completely separate, off-label story of use by men who take it alongside anabolic steroids or testosterone to push estrogen down. This page is meant to inform and reduce harm. It contains no doses, cycles, stacks, or post-cycle protocols.

What it is

Anastrozole is a selective, non-steroidal (Type II), reversible/competitive aromatase inhibitor (AI) — meaning it gently and temporarily blocks one specific enzyme. That enzyme, aromatase (gene name CYP19A1), runs the last and slowest step that turns androgens (male-type hormones such as androstenedione and testosterone) into estrogens (estrone and estradiol). This happens out in tissues like fat, muscle, and liver. Block the enzyme, and estrogen levels in the blood drop.

After menopause, most of a woman’s estrogen comes from this conversion in the body’s tissues, so anastrozole brings estradiol (the main form of estrogen) down a lot — roughly 80 to 90 percent. At normal doses it does not noticeably interfere with the adrenal hormones (cortisol-type steroids or aldosterone, which help manage stress and fluid balance).

Here is a key point for the non-medical side of things. In people who haven’t gone through menopause and in men, the body has a feedback loop — the hypothalamic-pituitary-gonadal (HPG) axis, the brain-to-gonad signaling chain that controls sex hormones. When estrogen falls, this loop fights back by releasing more gonadotropins (the brain signals that tell the gonads to ramp up), which softens the estrogen drop and pushes testosterone higher. That rebound is exactly why men misuse it (more on that below) — and it’s also why anastrozole doesn’t work well, and isn’t appropriate, as a standalone treatment in premenopausal women.

The claims

Medical use is clearly mapped out: treating HR+ breast cancer (a type that grows in response to hormones) in postmenopausal women, both as follow-up treatment after surgery and for advanced disease, plus preventive use in postmenopausal women at high risk. There’s also experimental off-label hormone use in certain children’s protocols for short stature or early puberty (for example, the GAIL study, which paired anastrozole with leuprorelin in girls maturing early) — but that is not an approved use.

Athletes and bodybuilders use anastrozole off-label, outside any medical setting, for a different reason. Taken alongside anabolic-androgenic steroids (AAS) or testosterone (TRT) that convert into estrogen, it’s used to push estrogen down and cut back on gynecomastia (male breast growth), water retention from high estrogen, and other high-estrogen side effects. In men it’s also used to raise the body’s own testosterone by lifting the estrogen “brake” on that brain-to-gonad feedback loop. USADA (the U.S. Anti-Doping Agency) says plainly that AIs get misused to “artificially keep androgen levels high” and to limit side effects like breast growth in men. This is unapproved use.

What the evidence actually shows

The human evidence for anastrozole’s approved uses is genuinely strong — built on large, randomized cancer trials. The evidence for using it for performance or physique in healthy men is essentially nonexistent.

• ATAC trial (follow-up treatment after surgery, about 9,366 postmenopausal women): this compared anastrozole, tamoxifen, and the two together. At 68 months of follow-up, anastrozole did better on disease-free survival (time lived without the cancer coming back) and time-to-recurrence, lowered the rate of cancer in the opposite breast, and caused fewer uterine-lining and blood-clot problems — but caused more joint pain and more fractures than tamoxifen (HR 0.87, 95% CI 0.78–0.97 for disease-free survival at the 5-year readout; “HR” here is a hazard ratio, where below 1.0 favors anastrozole). The 10-year analysis confirmed a lasting drop in recurrence, with no difference in overall survival. ATAC made anastrozole a go-to first choice for this kind of after-surgery hormone treatment in this group.
• IBIS-II prevention trial (3,864 high-risk postmenopausal women, anastrozole vs. a placebo): roughly a 50 percent drop in new breast cancers during the treatment period (first results HR about 0.47; over the long term about a 49 percent reduction, 85 vs. 165 cases at a median of roughly 131 months). Long-term follow-up showed the protection held up, with no extra fractures or heart disease — pointing to a real prevention effect.
• Lipids (blood fats like cholesterol): the evidence is mixed but generally small for anastrozole. Pooled analyses show minor, inconsistent changes; the data suggest two related drugs, letrozole and exemestane, worsen blood fats more than anastrozole does, while anastrozole has little harmful effect (and may be neutral or even slightly favorable). It’s not as clearly protective as tamoxifen.
• Bone: AI treatment consistently shows lower bone density and a higher fracture risk than tamoxifen or placebo — the best-documented downside.
• Men / performance use: careful physiology research (Finkelstein et al., NEJM 2013) shows that lowering estrogen in men increases body fat and reduces libido and sexual function, and that AI-driven estrogen suppression contributes to bone loss even when testosterone stays normal. In short, estrogen isn’t just a “side-effect hormone” in men — it does real work. There is no solid evidence that anastrozole safely or reliably improves athletic performance or body composition in healthy men, and its non-medical use has never been studied for safety in that setting.

Legal and regulatory status

US — prescription drug, not a controlled substance. Anastrozole is legal only with a valid prescription. It is not scheduled under the Controlled Substances Act (the law that ranks drugs by abuse risk). Selling or handing it out without a prescription, or putting it in products marketed as “dietary supplements,” is against the law — the FDA and USADA point out that AI-type compounds such as arimistane don’t qualify as a dietary ingredient and can’t legally be in supplements. One label detail worth getting right: the DailyMed label lists “may cause fetal harm” under Warnings / Use in Pregnancy (advising reliable contraception during treatment and for at least 3 weeks after), rather than formally under “Contraindications” — but the bottom line, avoid in pregnancy, is the same either way.

For context on the wider world of “support compounds” people run into alongside it:

• Other AIs (letrozole, exemestane, testolactone) and SERMs / anti-estrogens (tamoxifen, clomifene, raloxifene, toremifene) are likewise prescription and non-controlled.
• Mesterolone (Proviron) and fluoxymesterone (Halotestin) are anabolic-androgenic steroids, which makes them Schedule III controlled substances under the Anabolic Steroid Control Act.
• DNP (2,4-dinitrophenol) is not approved for people to consume; the FDA has warned against it for decades, and it has a long history of deadly poisonings. It is not a medicine (see Safety).
• Insulin and liothyronine (T3, a thyroid hormone) are prescription drugs.

Anti-doping (WADA 2026 Prohibited List). Aromatase inhibitors (including anastrozole), anti-estrogens, and SERMs sit in Class S4, “Hormone and Metabolic Modulators,” and are banned at all times (both in and out of competition):

• S4.1 Aromatase inhibitors: anastrozole, letrozole, exemestane, testolactone, formestane, aminoglutethimide, arimistane, and others. For 2026, WADA added 2-phenylbenzo[h]chromen-4-one (for example, α-naphthoflavone / 7,8-benzoflavone) as a sample AI.
• S4.2 Anti-estrogenic substances / SERMs: anti-estrogens and SERMs (historically tamoxifen, clomifene, raloxifene, toremifene; the current WADA-listed example includes bazedoxifene).
• S4.4 Insulins and other metabolic modulators: insulins are banned here, and for 2026 WADA added BAM15 (an AMPK activator — a compound that nudges a cellular energy-sensing pathway) as an S4.4 metabolic modulator.

Separately, anabolic agents (S1) cover AAS such as mesterolone and fluoxymesterone (banned at all times), and DNP falls under the metabolic-modulator / non-approved-substance rules and is banned.

Safety

Anastrozole / AIs specifically:

• Bone loss and fractures — the best-documented harm; AIs speed up the loss of bone density and raise fracture risk (clear in ATAC).
• Aromatase-inhibitor arthralgia syndrome — common, sometimes severe joint pain and stiffness (“arthralgia” just means joint pain); one of the main reasons people stop taking it.
• Hot flushes (sudden waves of heat, the “vasomotor” symptoms), fatigue, mood effects, and possible unfavorable shifts in blood fats (variable, and generally small for anastrozole).
• In men, pushing estrogen too low can lead to lower libido and erection problems, more body and belly fat, and bone loss — because estrogen is essential to men’s bone and metabolic health (Finkelstein, NEJM 2013).
• Avoid in pregnancy (fetal harm, per the label); no role in premenopausal women unless their ovaries are also suppressed.

The genuinely dangerous companions people use alongside it — an honest comparison:

• DNP (2,4-dinitrophenol) — the most lethal compound in this whole landscape, and it kills people. It’s a “mitochondrial uncoupler,” meaning it forces cells to burn energy as runaway heat, which causes fatal overheating with NO antidote. Deaths have happened even at “typical” misuse amounts; all doctors can do is cool the body and provide supportive care. DNP has caused death after death and is not safe in any amount for people to consume.
• Insulin (misused by non-diabetics or as a PED) — can cause fast, severe, potentially deadly low blood sugar, seizures, permanent brain injury, and death; the effect is unpredictable and unforgiving once you’re outside medical control.
• SERMs (tamoxifen and others) — risk of blood clots (in the lungs, legs, or brain) and effects on the uterine lining.
• T3 (liothyronine) — misusing this thyroid hormone causes racing or irregular heartbeats, strain on the heart, bone loss, and shutdown of the body’s own thyroid signaling; stopping suddenly can trigger a rebound into an underactive thyroid.
• AAS (mesterolone, fluoxymesterone) — liver damage (especially with oral 17α-alkylated forms like fluoxymesterone), bad effects on blood fats and the heart, and suppression of the body’s own sex-hormone signaling.

None of the PED-support uses above are FDA-approved. Non-medical use means no medical monitoring, and with non-pharmacy product you simply can’t know how pure it is or whether it’s contaminated.

Bottom line

Anastrozole is a non-steroidal aromatase inhibitor — a prescription breast-cancer drug, not a SERM and not a peptide. In its approved group, postmenopausal women, the human evidence is strong: large randomized trials (ATAC, IBIS-II) show real benefit in treating and preventing HR+ breast cancer, with bone loss and joint pain as the clearest harms. Its off-label use by men to lower estrogen is based on real hormone biology, but it’s never been studied for safety in healthy people, and careful research (Finkelstein, NEJM 2013) shows that driving men’s estrogen too low backfires — more fat, less libido, and bone loss. It’s a prescription drug (not a controlled substance) and is banned in sport at all times under WADA S4.1. Of the compounds people use alongside it, DNP is the standout danger: it has no antidote and has killed people.

Evidence grade: 10/10 · Established.

Sources

• DailyMed — Anastrozole tablet label
• FDA Arimidex (anastrozole) prescribing information (accessdata)
• HemOnc.org — Anastrozole (Arimidex)
• ATAC first results, Lancet 2002
• ATAC 5-year completion, Lancet 2005 (PMID 15639680)
• ATAC long-term side-effect profile, Lancet Oncol 2006
• ATAC 10-year analysis, Lancet Oncol 2010 (PMID 21087898)
• Meta-analysis anastrozole vs tamoxifen, Trials 2008 (PMID 18664277)
• IBIS-II prevention, first results, Lancet 2014 (PMID 24333009)
• IBIS-II long-term results, Lancet 2020 (PMID 31839281)
• Effect of anastrozole on lipid profile, Clinical Therapeutics 2022 (PMID 36031476)
• AIs and plasma lipid changes in postmenopausal women, meta-analysis (PMC10970985)
• Effects of AIs on lipids and thrombosis, review (PMC2361692)
• Finkelstein et al., Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men, NEJM 2013 (PMID 24350954)
• WADA — The Prohibited List (official)
• USADA — Aromatase Inhibitors explainer
• USADA — 2026 Prohibited List changes (2-phenylbenzo[h]chromen-4-one AI + BAM15 AMPK activator)
• Drugs.com — WADA S4 Hormone and Metabolic Modulators
• Anastrozole + leuprorelin in early-maturing girls (GAIL study, PMC4799269)